EMA Authorised: Strensiq (asfotase alfa) — Alexion Europe SAS

View source ↗

Summary

The EMA authorised Strensiq (asfotase alfa) for the treatment of hypophosphatasia. The marketing authorisation holder is Alexion Europe SAS, and the medicine ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• STRENSIQ (asfotase alfa)

Snippet

Status: Authorised. Therapeutic area: Hypophosphatasia. MAH: Alexion Europe SAS. Decision date: 16/02/2026. Orphan medicine